Tag Archives: effects
#437261 How AI Will Make Drug Discovery ...
If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?
Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.
But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.
Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.
GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.
But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.
He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.
Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”
The results have turned what was once a decade-long war into a month-long skirmish.
In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.
Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.
They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.
Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.
Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.
But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.
Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.
On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.
Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.
One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.
Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.
Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.
Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.
Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”
How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?
Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”
If you’d like to learn more and consider joining our 2021 membership, apply here.
(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.
(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)
This article originally appeared on diamandis.com. Read the original article here.
Image Credit: andreas160578 from Pixabay Continue reading
#436962 Scientists Engineered Neurons to Make ...
Electricity plays a surprisingly powerful role in our bodies. While most people are aware that it plays a crucial role in carrying signals to and from our nerves, our bodies produce electric fields that can do everything from helping heal wounds to triggering the release of hormones.
Electric fields can influence a host of important cellular behavior, like directional migration, proliferation, division, or even differentiation into different cell types. The work of Michael Levin at Tufts University even suggests that electrical fields may play a crucial role in the way our bodies organize themselves.
This has prompted considerable interest in exploiting our body’s receptiveness to electrical stimulation for therapeutic means, but given the diffuse nature of electrical fields a key challenge is finding a way to localize these effects. Conductive polymers have proven a useful tool in this regard thanks to their good electrical properties and biocompatibility, and have been used in everything from neural implants to biosensors.
But now, a team at Stanford University has developed a way to genetically engineer neurons to build the materials into their own cell membranes. The approach could make it possible to target highly specific groups of cells, providing unprecedented control over the body’s response to electrical stimulation.
In a paper in Science, the team explained how they used re-engineered viruses to deliver DNA that hijacks cells’ biosynthesis machinery to create an enzyme that assembles electroactive polymers onto their membranes. This changes the electrical properties of the cells, which the team demonstrated could be used to control their behavior.
They used the approach to modulate neuronal firing in cultures of rat hippocampal neurons, mouse brain slices, and even human cortical spheroids. Most impressively, they showed that they could coax the neurons of living C. elegans worms to produce the polymers in large enough quantities to alter their behavior without impairing the cells’ natural function.
Translating the idea to humans poses major challenges, not least because the viruses used to deliver the genetic changes are still a long way from being approved for clinical use. But the ability to precisely target specific cells using a genetic approach holds enormous promise for bioelectronic medicine, Kevin Otto and Christine Schmidt from the University of Florida say in an accompanying perspective.
Interest is booming in therapies that use electrical stimulation of neural circuits as an alternative to drugs for diseases as varied as arthritis, Alzheimer’s, diabetes, and cardiovascular disease, and hundreds of clinical trials are currently underway.
At present these approaches rely on electrodes that can provide some level of localization, but because different kinds of nerve cells are often packed closely together it’s proven hard to stimulate exactly the right nerves, say Otto and Schmidt. This new approach makes it possible to boost the conductivity of specific cell types, which could make these kinds of interventions dramatically more targeted.
Besides disease-focused bioelectronic interventions, Otto and Schmidt say the approach could prove invaluable for helping to interface advanced prosthetics with patients’ nervous systems by making it possible to excite sensory neurons without accidentally triggering motor neurons, or vice versa.
More speculatively, the approach could one day help create far more efficient bridges between our minds and machines. One of the major challenges for brain-machine interfaces is recording from specific neurons, something that a genetically targeted approach might be able to help greatly with.
If the researchers can replicate the ability to build electronic-tissue “composites” in humans, we may be well on our way to the cyborg future predicted by science fiction.
Image Credit: Gerd Altmann from Pixabay Continue reading
#436546 How AI Helped Predict the Coronavirus ...
Coronavirus has been all over the news for the last couple weeks. A dedicated hospital sprang up in just eight days, the stock market took a hit, Chinese New Year celebrations were spoiled, and travel restrictions are in effect.
But let’s rewind a bit; some crucial events took place before we got to this point.
A little under two weeks before the World Health Organization (WHO) alerted the public of the coronavirus outbreak, a Canadian artificial intelligence company was already sounding the alarm. BlueDot uses AI-powered algorithms to analyze information from a multitude of sources to identify disease outbreaks and forecast how they may spread. On December 31st 2019, the company sent out a warning to its customers to avoid Wuhan, where the virus originated. The WHO didn’t send out a similar public notice until January 9th, 2020.
The story of BlueDot’s early warning is the latest example of how AI can improve our identification of and response to new virus outbreaks.
Predictions Are Bad News
Global pandemic or relatively minor scare? The jury is still out on the coronavirus. However, the math points to signs that the worst is yet to come.
Scientists are still working to determine how infectious the virus is. Initial analysis suggests it may be somewhere between influenza and polio on the virus reproduction number scale, which indicates how many new cases one case leads to.
UK and US-based researchers have published a preliminary paper estimating that the confirmed infected people in Wuhan only represent five percent of those who are actually infected. If the models are correct, 190,000 people in Wuhan will be infected by now, major Chinese cities are on the cusp of large-scale outbreaks, and the virus will continue to spread to other countries.
Finding the Start
The spread of a given virus is partly linked to how long it remains undetected. Identifying a new virus is the first step towards mobilizing a response and, in time, creating a vaccine. Warning at-risk populations as quickly as possible also helps with limiting the spread.
These are among the reasons why BlueDot’s achievement is important in and of itself. Furthermore, it illustrates how AIs can sift through vast troves of data to identify ongoing virus outbreaks.
BlueDot uses natural language processing and machine learning to scour a variety of information sources, including chomping through 100,000 news reports in 65 languages a day. Data is compared with flight records to help predict virus outbreak patterns. Once the automated data sifting is completed, epidemiologists check that the findings make sense from a scientific standpoint, and reports are sent to BlueDot’s customers, which include governments, businesses, and public health organizations.
AI for Virus Detection and Prevention
Other companies, such as Metabiota, are also using data-driven approaches to track the spread of the likes of the coronavirus.
Researchers have trained neural networks to predict the spread of infectious diseases in real time. Others are using AI algorithms to identify how preventive measures can have the greatest effect. AI is also being used to create new drugs, which we may well see repeated for the coronavirus.
If the work of scientists Barbara Han and David Redding comes to fruition, AI and machine learning may even help us predict where virus outbreaks are likely to strike—before they do.
The Uncertainty Factor
One of AI’s core strengths when working on identifying and limiting the effects of virus outbreaks is its incredibly insistent nature. AIs never tire, can sift through enormous amounts of data, and identify possible correlations and causations that humans can’t.
However, there are limits to AI’s ability to both identify virus outbreaks and predict how they will spread. Perhaps the best-known example comes from the neighboring field of big data analytics. At its launch, Google Flu Trends was heralded as a great leap forward in relation to identifying and estimating the spread of the flu—until it underestimated the 2013 flu season by a whopping 140 percent and was quietly put to rest.
Poor data quality was identified as one of the main reasons Google Flu Trends failed. Unreliable or faulty data can wreak havoc on the prediction power of AIs.
In our increasingly interconnected world, tracking the movements of potentially infected individuals (by car, trains, buses, or planes) is just one vector surrounded by a lot of uncertainty.
The fact that BlueDot was able to correctly identify the coronavirus, in part due to its AI technology, illustrates that smart computer systems can be incredibly useful in helping us navigate these uncertainties.
Importantly, though, this isn’t the same as AI being at a point where it unerringly does so on its own—which is why BlueDot employs human experts to validate the AI’s findings.
Image Credit: Coronavirus molecular illustration, Gianluca Tomasello/Wikimedia Commons Continue reading